New dashboard aims to make leukemia trials more inclusive

NCT ID NCT06795139

Completed Knowledge-focused Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests a data visualization tool called the Trial Enrollment Diversity Dashboard (TEDD) designed to help doctors see how diverse their clinical trial enrollments are. The goal is to overcome racial and ethnic disparities in leukemia trial participation. The study enrolls healthcare professionals who treat leukemia patients and measures how often they use the dashboard over four three-month periods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trial Enrollment Diversity Dashboard (TEDD) behavioral intervention
What this could lead to: If successful, this dashboard could help make clinical trials more representative of the diverse populations they aim to serve.
What could go wrong: This is a small feasibility pilot with only 12 participants, so results may not apply broadly. The tool's impact on actual diversity is not yet measured.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia leukemia lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LEUKEMIA LEUKEMIA

Contacts and locations

Show contact details

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.